Stockscreener 앱 받기
5.39
1.10%
-0.06
시간 외 거래:
5.50
0.11
+2.04%
전일 마감가:
$5.45
열려 있는:
$5.22
하루 거래량:
80,856
Relative Volume:
0.93
시가총액:
$91.15M
수익:
-
순이익/손실:
$-14.88M
주가수익비율:
-5.50
EPS:
-0.98
순현금흐름:
$-10.29M
1주 성능:
-16.69%
1개월 성능:
-21.66%
6개월 성능:
-24.51%
1년 성능:
-43.62%
1일 변동 폭
$5.03
$5.565
1주일 범위
$5.03
$6.6672
52주 변동 폭
$4.75
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
명칭
Coya Therapeutics Inc
전화
650.739.3939
주소
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.39 | 91.15M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-04 | 개시 | D. Boral Capital | Buy |
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe
GMP Production of Exosomes Slated for Later This Year - streetwisereports.com
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - Defense World
Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases - Streetwise Reports
What is Chardan Capital’s Forecast for COYA FY2025 Earnings? - Defense World
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Yahoo Finance
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Yahoo Finance
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - Yahoo
Coya Therapeutics advances Treg exosome production By Investing.com - Investing.com South Africa
Coya Therapeutics advances Treg exosome production - Investing.com India
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Joplin Globe
Revolutionary Treg Exosome Treatment Could Transform Neurodegenerative Disease Therapy - Stock Titan
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
(COYA) Trading Report - news.stocktradersdaily.com
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital - Defense World
Coya Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
BTIG maintains Buy on Coya Therapeutics, target at $15 By Investing.com - Investing.com Canada
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Coya Therapeutics, Inc. SEC 10-K Report - TradingView
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire
Coya Therapeutics Secures $18.85M Funding, Reports Breakthrough in Alzheimer's Treatment - Stock Titan
Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering - Business Wire
Coya Therapeutics Announces Closing of $26.5 Million Private Placement - Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Where are the Opportunities in (COYA) - Stock Traders Daily
Coya Therapeutics (COYA) to Release Earnings on Tuesday - Defense World
Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Market Watch Highlights: Coya Therapeutics Inc (COYA) Ends on an Upturn Note at 6.88 - The Dwinnex
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases - MSN
ALS drug failures and why COYA 302 is different - Digital Journal
Coya Therapeutics (NASDAQ:COYA) Trading Up 4.5% – Should You Buy? - Defense World
(COYA) Investment Analysis - Stock Traders Daily
Can GLP-1 Agonists Transform Alzheimer's Treatment? Coya Therapeutics Experts Weigh In - StockTitan
Coya reports promising Alzheimer's treatment study results - MSN
Long Term Trading Analysis for (COYA) - Stock Traders Daily
Robust Growth in AI in Clinical Trials Market (2025-2032): - openPR
Newbridge Financial Services Group Inc. Makes New Investment in Coya Therapeutics, Inc. (NASDAQ:COYA) - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from Chardan Capital - MarketBeat
(COYA) Trading Advice - Stock Traders Daily
BTIG maintains Coya Therapeutics stock buy rating, $15 target - MSN
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD (NASDAQ:COYA) - Seeking Alpha
Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch - Seeking Alpha
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's disease - Marketscreener.com
Coya Therapeutics Inc (COYA) Shares Rise Despite Market Challenges - The News Heater
Coya reports promising Alzheimer’s treatment study results By Investing.com - Investing.com Nigeria
Coya Therapeutics Inc (COYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
자본화:
|
볼륨(24시간):